Emerald Bioscience Inc. (EMBI)
| Market Cap | 22.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -206,540 |
| Shares Out | 256.76M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jan 19, 2021 |
| Last Price | $0.1100 |
| Previous Close | $0.0900 |
| Change ($) | 0.0200 |
| Change (%) | 22.22% |
| Day's Open | 0.1200 |
| Day's Range | 0.0800 - 0.2460 |
| Day's Volume | 7,770,823 |
| 52-Week Range | 0.025 - 0.246 |
News
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic can...
Name change reflects Company's evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021 Name c...
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic c...
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, propr...
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma
The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as ...
Renewed team and capital focused on advancing lead compound for glaucoma into human studies
San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...
Renewed team and capital focused on advancing lead compound for glaucoma into clinical development Renewed team and capital focused on advancing lead compound for glaucoma into clinical develo...
Renewed team and capital focused on advancing lead compound for glaucoma into clinical development
Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to a...
Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to ...
Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue mod...
After reporting some strong results from its studies last month, cannabinoid biopharmaceutical company Emerald Bioscience Inc recently made headlines again.
About EMBI
Emerald Bioscience, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use ... [Read more...]
| Industry Biotechnology | Founded 2012 |
| CEO Brian Murphy | Employees 4 |
| Stock Exchange OTCMKTS | Ticker Symbol EMBI |